步长制药(603858.SH)子公司签订两项技术开发合同

智通财经07-23

智通财经APP讯，步长制药(603858.SH)发布公告，2026年7月23日，公司全资子公司保定天浩制药有限公司(简称“保定天浩”)与北京新力妍生物科技有限公司(简称“北京新力妍”)签订两项《技术开发(委托)合同》，委托北京新力妍按照国家现行《医疗器械注册管理办法》及相关技术指导原则，开展注射用丝素蛋白填充剂与注射用羟基磷酸钙填充剂的研发、注册申报、受托生产等合作事宜。两项产品均为国家三类...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2653449743?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-23 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653449743","market":"us","top_or_hot":-1,"title":"步长制药(603858.SH)子公司签订两项技术开发合同","media":"智通财经","content":"<div>\n<p>智通财经APP讯，步长制药(603858.SH)发布公告，2026年7月23日，公司全资子公司保定天浩制药有限公司(简称“保定天浩”)与北京新力妍生物科技有限公司(简称“北京新力妍”)签订两项《技术开发(委托)合同》，委托北京新力妍按照国家现行《医疗器械注册管理办法》及相关技术指导原则，开展注射用丝素蛋白填充剂与注射用羟基磷酸钙填充剂的研发、注册申报、受托生产等合作事宜。两项产品均为国家三类...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1471460.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>步长制药(603858.SH)子公司签订两项技术开发合同</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n步长制药(603858.SH)子公司签订两项技术开发合同\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 17:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1471460.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，步长制药(603858.SH)发布公告，2026年7月23日，公司全资子公司保定天浩制药有限公司(简称“保定天浩”)与北京新力妍生物科技有限公司(简称“北京新力妍”)签订两项《技术开发(委托)合同》，委托北京新力妍按照国家现行《医疗器械注册管理办法》及相关技术指导原则，开展注射用丝素蛋白填充剂与注射用羟基磷酸钙填充剂的研发、注册申报、受托生产等合作事宜。两项产品均为国家三类...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1471460.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1471460.html","article_id":"2653449743","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653449743","pubTimestamp":1784798995,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，步长制药 发布公告，2026年7月23日，公司全资子公司保定天浩制药有限公司与北京新力妍生物科技有限公司签订两项《技术开发(委托)合同》，委托北京新力妍按照国家现行《医疗器械注册管理办法》及相关技术指导原则，开展注射用丝素蛋白填充剂与注射用羟基磷酸钙填充剂的研发、注册申报、受托生产等合作事宜。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603858":"步长制药","BK0239":"医药制造","BK0196":"行业龙头"},"translate_title":"Buchang Pharmaceuticals (603858.SH) Subsidiaries Sign Two Technology Development Contracts","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603858":1.5},"content_text":"智通财经APP讯，步长制药(603858.SH)发布公告，2026年7月23日，公司全资子公司保定天浩制药有限公司(简称“保定天浩”)与北京新力妍生物科技有限公司(简称“北京新力妍”)签订两项《技术开发(委托)合同》，委托北京新力妍按照国家现行《医疗器械注册管理办法》及相关技术指导原则，开展注射用丝素蛋白填充剂与注射用羟基磷酸钙填充剂的研发、注册申报、受托生产等合作事宜。两项产品均为国家三类医疗器械。据悉，注射用丝素蛋白填充剂适应症为治疗中面部容量缺失，注射用羟基磷酸钙填充剂适应症为治疗下颌缘轮廓缺失。此次保定天浩与第三方签订《技术开发(委托)合同》，有利于增强公司产品研发能力，扩大产品研发范围，一定程度上节约了公司产品临床试验的时间和成本，保障项目的顺利进行。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653449743","isCrawlerRequest":true}